NORTHWOOD, OHIO – February 8, 2012 – NAMSA, a leading medical device research organization, recently announced the opening of its newest office located near Frankfurt, Germany, which is staffed to provide clinical research and consulting services throughout Europe. This new location will serve clients seeking regulatory approval to market medical devices in Europe, in addition to providing regulatory and clinical trial support to European companies seeking clearance from the U.S. Food and Drug Administration.
European market approval has emerged as a preferred pathway for medical device manufacturers primarily due to more efficient approval processes. “The placement of this office reinforces NAMSA’s commitment to helping our clients design and execute regulatory strategies, develop new therapies and launch them in the most efficient manner possible,” said John Gorski, President and CEO.
NAMSA’s testing laboratory in Lyon, France (Biomatech) has provided non-clinical safety and efficacy studies to medical device companies since 1986. “The combination of non-clinical and clinical research expertise at our European locations enables NAMSA to provide our clients with a higher level of continuity, consistency and convenience throughout the product development process,” added Gorski.
NAMSA (www.namsa.com) is a global medical device research organization providing a comprehensive range of services to prove efficacy, non-clinical and clinical safety of medical devices, IVDs and combination products. For more than 45 years, NAMSA clients have utilized its testing and consulting services to bring safe and effective therapies to market.